UNSPSC 51291802: Eclanamine

This classification denotes an antidepressant agent with the molecular formula C16H22CL2N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 5Y67H9W4KQ chemically known as propanamide, n-(3,4-dichlorophenyl)-n-(2-(dimethylamino)cyclopentyl)-, trans-(+/-)- but generally known as eclanamine, which bears US NIH Compound Identifier 130380. European Medicines Agency schedules Eclanamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06447MIG.

UNSPSC 51291802 Eclanamine, a Commodity code, covers pharmaceutical products including naloxone, generic multi-source pharmaceuticals, and over-the-counter medications that state and local governments procure for community health, emergency response, and employee health benefit programs. State and local issuing bodies soliciting under this code include county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances. The work involves direct procurement of finished pharmaceutical products with specified National Drug Codes, compliance with FDA manufacturing standards and Drug Supply Chain Security Act requirements, and established relationships with authorized pharmaceutical wholesalers. Vendors must maintain current Good Manufacturing Practices certification, meet insurance requirements including commercial general liability coverage, and comply with E-Verify employment eligibility verification.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted an RFI on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program connecting state pharmacy benefit programs directly with pharmaceutical manufacturers. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 on January 20, 2026, to establish multi-award contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026, and contract effectiveness set for July 1, 2026. The Minnesota solicitation emphasizes price competitiveness at 75 percent of evaluation weight and requires vendors to maintain relationships with at least two of three authorized wholesalers.